Literature DB >> 27825764

Synthesis of novel Ral inhibitors: An in vitro and in vivo study.

Chao Yan1, Dan Theodorescu2, Bettina Miller3, Amit Kumar3, Vijay Kumar3, David Ross3, Michael F Wempe4.   

Abstract

Chemical synthesis was performed to produce a series of 6-amino-1,3-disubstituted-4-phenyl-1,4-dihydro pyrano[2,3-c]pyrazole-5-carbonitrile compounds (14-57) which were characterized by 1H NMR, 13C NMR and LC/MS-MS. These compounds were assessed for their effect on the in vitro anchorage independent growth of human lung cancer cell line H2122 and IC50 values calculated. Two of the more potent compounds, BQU057 40 and BQU082 57 also displayed a dose dependent effect on RalA and RalB activity in H2122 spheroids using the common RalBP1 pull-down assay. Mouse PK and tissue distribution studies on 40 and 57 were performed and demonstrated that parent drug was present in tumor 3.0h post ip (50mg/Kg) dose.
Copyright © 2016 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemical synthesis; Ral inhibitor; Tissue distribution

Mesh:

Substances:

Year:  2016        PMID: 27825764      PMCID: PMC5301652          DOI: 10.1016/j.bmcl.2016.10.021

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  17 in total

Review 1.  RLIP76, a novel transporter catalyzing ATP-dependent efflux of xenobiotics.

Authors:  Sanjay Awasthi; Rajendra Sharma; Sharad S Singhal; Piotr Zimniak; Yogesh C Awasthi
Journal:  Drug Metab Dispos       Date:  2002-12       Impact factor: 3.922

Review 2.  Hyperactive Ras in developmental disorders and cancer.

Authors:  Suzanne Schubbert; Kevin Shannon; Gideon Bollag
Journal:  Nat Rev Cancer       Date:  2007-04       Impact factor: 60.716

3.  Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis.

Authors:  Pascal Peschard; Afshan McCarthy; Valérie Leblanc-Dominguez; Maggie Yeo; Sabrina Guichard; Gordon Stamp; Christopher J Marshall
Journal:  Curr Biol       Date:  2012-10-11       Impact factor: 10.834

4.  Ral activation promotes melanomagenesis.

Authors:  P A Zipfel; D C Brady; D F Kashatus; B D Ancrile; D S Tyler; C M Counter
Journal:  Oncogene       Date:  2010-06-21       Impact factor: 9.867

Review 5.  Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer.

Authors:  P J Roberts; C J Der
Journal:  Oncogene       Date:  2007-05-14       Impact factor: 9.867

6.  Discovery and characterization of small molecules that target the GTPase Ral.

Authors:  Chao Yan; Degang Liu; Liwei Li; Michael F Wempe; Sunny Guin; May Khanna; Jeremy Meier; Brenton Hoffman; Charles Owens; Christina L Wysoczynski; Matthew D Nitz; William E Knabe; Mansoor Ahmed; David L Brautigan; Bryce M Paschal; Martin A Schwartz; David N M Jones; David Ross; Samy O Meroueh; Dan Theodorescu
Journal:  Nature       Date:  2014-09-14       Impact factor: 49.962

7.  Activation of the RalGEF/Ral pathway promotes prostate cancer metastasis to bone.

Authors:  JuanJuan Yin; Claire Pollock; Kirsten Tracy; Monika Chock; Philip Martin; Michael Oberst; Kathleen Kelly
Journal:  Mol Cell Biol       Date:  2007-08-20       Impact factor: 4.272

8.  Expression of ral GTPases, their effectors, and activators in human bladder cancer.

Authors:  Steven Christopher Smith; Gary Oxford; Alexander S Baras; Charles Owens; Dmytro Havaleshko; David L Brautigan; Martin K Safo; Dan Theodorescu
Journal:  Clin Cancer Res       Date:  2007-07-01       Impact factor: 12.531

9.  Drugging the Ral GTPase.

Authors:  Chao Yan; David N M Jones; Dan Theodorescu
Journal:  Small GTPases       Date:  2015

10.  Differential involvement of RalA and RalB in colorectal cancer.

Authors:  Timothy D Martin; Channing J Der
Journal:  Small GTPases       Date:  2012 Apr-Jun
View more
  1 in total

Review 1.  Ral signaling pathway in health and cancer.

Authors:  Adel Rezaei Moghadam; Elham Patrad; Elham Tafsiri; Warner Peng; Benjamin Fangman; Timothy J Pluard; Anthony Accurso; Michael Salacz; Kushal Shah; Brandon Ricke; Danse Bi; Kyle Kimura; Leland Graves; Marzieh Khajoie Najad; Roya Dolatkhah; Zohreh Sanaat; Mina Yazdi; Naeimeh Tavakolinia; Mohammad Mazani; Mojtaba Amani; Saeid Ghavami; Robyn Gartell; Colleen Reilly; Zaid Naima; Tuba Esfandyari; Faris Farassati
Journal:  Cancer Med       Date:  2017-10-18       Impact factor: 4.452

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.